{"disease":{"id":"trastuzumab-emtansine","name":"trastuzumab emtansine"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06928818","title":"Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06125834","title":"Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}